Abstract:One of the neuropathological hallmarks of Alzheimer's disease is the presence of β-amyloid (Aβ)-containing neuritic plaques. Aβ is produced by the proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretase enzymes. Thus, inhibition of β-secretase (BACE1) is a promising disease modifying approach for Alzheimer's disease. Several high affinity BACE inhibitors have been described that reduce plasma Aβ in vivo. Although this may be sufficient to provide clinical benefit (e.g., via peripheral sink), our goal was to identify BACE inhibitors that substantially reduced (>25%) Aβ in the brain. To support ongoing medicinal chemistry SAR efforts to identify BACE inhibitors that would reduce Aβ in the brain, we used lowering of Aβ1-40 in cerebrospinal fluid (CSF) as a marker of CNS BACE1 inhibition. We also switched our in vivo screening model from transgenic CRND8 mice expressing the Swedish and Indiana mutations in the human APP gene to non-transgenic rats and developed a sensitive rat Aβ1-40 immunoassay assay to support the in vivo screen. Our ex vivo binding studies and studies with heterozygous BACE1 mice supported the conclusion that BACE is not the rate limiting step for Aβ synthesis in the rodent brain and thus high occupancy of the BACE enzyme is likely required for brain efficacy. After focusing our SAR efforts around robust Aβ-lowering in rat CSF, several novel, potent, high affinity, orally available, brain penetrant BACE inhibitors were identified that substantially lowered CSF Aβ and more importantly, inhibited Aβ in the rat cortex. Based on our experience, brain exposures well in excess of inhibitor cell potency alone did not always result in substantial lowering of CSF or cortical Aβ, but that high brain exposure combined with sustained and substantial CSF efficacy was needed to observe Aβ-lowering in the cortex. Thus, we have identified several novel, potent BACE inhibitors with excellent Aβ-lowering activity in CSF and the brain which may be of use as disease modifying Alzheimer's disease therapeutics.

Discovery of SCH 900229, a Potent Presenilin 1 Selective γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease.

Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's Disease

Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer’s disease

Structure Activity Relationship Studies of Tricyclic Bispyran Sulfone Γ-Secretase Inhibitors

Design and Synthesis of Water Soluble Β-Aminosulfone Analogues of SCH 900229 As Γ-Secretase Inhibitors.

In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea Racemosa.

Spirocyclic Sulfamides As Β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer's Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies to Identify Centrally Efficacious Inhibitors.

Discovery of Novel, Potent BACE Inhibitors with Central Activity for the Treatment of Alzheimer's Disease

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease <i>in vitro</i> and <i>in vivo</i>

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo

Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine

Discovery of Novel Tacrine-Pyrimidone Hybrids As Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease.

Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

Discovery of Novel PDE9 Inhibitors Capable of Inhibiting Aβ Aggregation As Potential Candidates for the Treatment of Alzheimer’s Disease

Discovery of Compounds That Selectively Repress the Amyloidogenic Processing of the Amyloid Precursor Protein: Design, Synthesis and Pharmacological Evaluation of Diphenylpyrazoles

Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.

Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (ache) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease

Discovery of a Series of Selective and Cell Permeable Beta-Secretase (BACE1) Inhibitors by Fragment Linking with the Assistance of STD-NMR.